BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37343064)

  • 1. Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.
    Tantawy SI; Timofeeva N; Hernandez A; Sarkar A; Gandhi V
    Oncotarget; 2023 Jun; 14():653-655. PubMed ID: 37343064
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.
    Tantawy SI; Sarkar A; Hubner S; Tan Z; Wierda WG; Eldeib A; Zhang S; Kornblau S; Gandhi V
    Clin Cancer Res; 2023 Jan; 29(2):446-457. PubMed ID: 36346691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
    Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
    Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
    Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
    Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
    Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776
    [No Abstract]   [Full Text] [Related]  

  • 7. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety.
    Deng H; Huang M; Liu H; Zhang H; Liu L; Gao B; Li X; Li J; Niu Q; Zhang Z; Luan S; Zhang J; Jing Y; Liu D; Zhao L
    Bioorg Chem; 2022 Oct; 127():106018. PubMed ID: 35901526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.
    Liang X; Li X; Zhao Z; Nie Y; Yao Z; Ren W; Yang X; Hou X; Fang H
    Bioorg Chem; 2022 Apr; 121():105643. PubMed ID: 35150958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming.
    Conage-Pough JE; Boise LH
    FEBS J; 2018 Jul; 285(14):2626-2640. PubMed ID: 29775995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
    Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
    Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
    Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
    Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.
    Geserick P; Wang J; Feoktistova M; Leverkus M
    Cell Death Dis; 2014 Sep; 5(9):e1412. PubMed ID: 25210795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.